Clinical Outcomes and Safety of Concurrent Chemoradiotherapy in EGFR-Mutant Unresectable Stage III NSCLC
Patients with <i>EGFR</i>-mutant unresectable stage III NSCLC exhibited significantly shorter PFS than patients with <i>EGFR</i> wild-type NSCLC. The median PFS was generally consistent with that of the control arm in the LAURA trial. Increased pneumonitis risk necessitates close monitoring in patients with <i>EGFR</i>-mutant unresectable stage III NSCLC.
Authors
- Masafumi Yamaguchi (ORCID: https://orcid.org/0000-0002-5601-4749)
- Yuichi Ozawa (ORCID: https://orcid.org/0000-0003-3798-3488)
- Miyuki Abe (ORCID: https://orcid.org/0000-0002-6570-5226)
- Nobuyuki Yamamoto (ORCID: https://orcid.org/0000-0002-7342-0853)
- Atsushi Osoegawa (ORCID: https://orcid.org/0000-0002-8327-3631)
- Yasushi Goto
- Seiji Niho (ORCID: https://orcid.org/0000-0001-9480-5923)
- Satoshi Oizumi (ORCID: https://orcid.org/0000-0002-9742-1818)
- Katsuyuki Hotta (ORCID: https://orcid.org/0000-0002-0112-0843)
- Toshio Shimokawa (ORCID: https://orcid.org/0000-0002-2256-0282)
- Shinkichi Takamori (ORCID: https://orcid.org/0000-0001-8175-6798)
- Shunichi Sugawara (ORCID: https://orcid.org/0000-0002-3427-4558)
- Tetsuya Mitsudomi (ORCID: https://orcid.org/0000-0001-9860-8505)
- Yohei Takumi (ORCID: https://orcid.org/0000-0002-1171-9243)
- Hiroaki Okamoto (ORCID: https://orcid.org/0000-0003-3110-5545)
Institutions
- Oita University (JP)
- Wakayama Medical University (JP)
- National Hospital Organization Kyushu Cancer Center (JP)
- Okayama University Hospital (JP)
- Izumi City General Hospital (JP)
- Yokohama Municipal Citizen's Hospital (JP)
- Hamamatsu Medical Center (JP)
- Sendai Kousei Hospital (JP)
- Dokkyo Medical University (JP)
- Kindai University (JP)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2025-08-29
- DOI
- https://doi.org/10.1016/j.jtocrr.2025.100897
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00